The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

por La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., La Rosée, P.
Publicado 2020